Subject(s)
Humans , Helicobacter Infections/drug therapy , Clarithromycin/administration & dosage , Proton Pump Inhibitors/administration & dosage , Lansoprazole/administration & dosage , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Canada , Reproducibility of Results , Helicobacter pylori , Evidence-Based Medicine , Drug Therapy, Combination , Disease EradicationSubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Peptic Ulcer/drug therapy , Zinc/adverse effects , Zinc/therapeutic use , Zinc Sulfate/adverse effects , Zinc Sulfate/therapeutic use , Peptic Ulcer/complications , Zinc/administration & dosage , Drug Administration Schedule , Reproducibility of Results , Helicobacter pylori , Helicobacter Infections , Treatment Outcome , Zinc Sulfate/administration & dosage , Evidence-Based MedicineSubject(s)
Humans , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Helicobacter pylori , Helicobacter Infections/drug therapy , Organometallic Compounds/therapeutic use , Drug Therapy, Combination , Fluoroquinolones , Helicobacter Infections/complications , Recurrence , Reproducibility of Results , Treatment OutcomeABSTRACT
Systemic amyloidosis comprises a group of diseases characterized by low molecular weight subunit protein deposit in organs, including the gastrointestinal tract. The most frequent clinical manifestations are gastrointestinal bleeding, malabsorption syndrome, protein-losing enteropathy and chronic intestinal dysmotility. The diagnosis is confirmed with gastrointestinal tissue biopsy positive to Congo red stain or recognizing the amyloid fibrils by electron microscopy. The treatment is based in the management of gastrointestinal symptoms and chemotherapeutic drugs, including melphalan and prednisone or cyclophosphamide, bortezomib and prednisone. The bone marrow transplant is reserved for 70-year-old patients or younger without advanced comorbidities. We present a case of a patient with weight loss, anorexia, nausea and early satiety.
La amiloidosis sistémica a un conjunto de enfermedades caracterizadas por el depósito de subunidades fibrilares proteicas de bajo peso molecular en órganos, incluyendo el sistema digestivo. Sus manifestaciones clínicas más frecuentes son la hemorragia digestiva, síndrome malabsortivo, gastro-enteropatía perdedora de proteínas y dismotilidad gastrointestinal crónica. El diagnóstico se confirma con una biopsia de tejido gastrointestinal positiva a tinción rojo Congo o la visualización de fibrillas de amiloide mediante microscopia electrónica. El tratamiento está basado el manejo de los síntomas gastrointestinales y el oncológico, donde destacan esquemas quimioterapéuticos que incluyen melfalan y prednisona o ciclofosfamida, bortezomib y prednisona. El trasplante de médula ósea está reservado a pacientes menores de 70 años sin comorbilidades avanzadas. Presentamos en este artículo el caso de un paciente con baja de peso, anorexia, náuseas y saciedad precoz.